Compare Novartis AG (NVS) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Prologis Inc — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Prologis Inc trades at $138.59 (market cap $133.20B). The key difference: Novartis AG is far larger — about 2.2× Prologis Inc's market cap, and Prologis Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| NVS | PLD | |
|---|---|---|
Market Cap | $298.18B | $133.20B |
Sector | Health | Real Estate |
52-Week High | $168.62 | $149.96 |
52-Week Low | $119.31 | $104.81 |
Enterprise Value | $339.50B | $167.94B |
Dividend Yield | 3.02% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Prologis (PLD) trades at $140.16, up 0.73% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights the acquisition of SEGRO for up to $19.2 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show variability, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth, strategic acquisitions, and a 57% analyst buy rating with a $159.22 price target. Risks include high debt levels, with debt-to-asset ratio rising to 37.2 in 2025, and integration challenges from the SEGRO deal. Investors should weigh strong profitability against leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
